Your browser doesn't support javascript.
loading
The characteristics of pre-existing humoral imprint determine efficacy of S. aureus vaccines and support alternative vaccine approaches.
Caldera, J R; Tsai, Chih-Ming; Trieu, Desmond; Gonzalez, Cesia; Hajam, Irshad A; Du, Xin; Lin, Brian; Liu, George Y.
  • Caldera JR; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
  • Tsai CM; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
  • Trieu D; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
  • Gonzalez C; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
  • Hajam IA; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
  • Du X; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
  • Lin B; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA.
  • Liu GY; Department of Pediatrics, University of California, San Diego, La Jolla, CA 92093, USA; Division of Infectious Diseases, Rady Children's Hospital, San Diego, CA 92123, USA. Electronic address: gyliu@ucsd.edu.
Cell Rep Med ; 5(1): 101360, 2024 01 16.
Article en En | MEDLINE | ID: mdl-38232694
ABSTRACT
The failure of the Staphylococcus aureus (SA) IsdB vaccine trial can be explained by the recall of non-protective immune imprints from prior SA exposure. Here, we investigate natural human SA humoral imprints to understand their broader impact on SA immunizations. We show that antibody responses against SA cell-wall-associated antigens (CWAs) are non-opsonic, while antibodies against SA toxins are neutralizing. Importantly, the protective characteristics of the antibody imprints accurately predict the failure of corresponding vaccines against CWAs and support vaccination against toxins. In passive immunization platforms, natural anti-SA human antibodies reduce the efficacy of the human monoclonal antibodies suvratoxumab and tefibazumab, consistent with the results of their respective clinical trials. Strikingly, in the absence of specific humoral memory responses, active immunizations are efficacious in both naive and SA-experienced mice. Overall, our study points to a practical and predictive approach to evaluate and develop SA vaccines based on pre-existing humoral imprint characteristics.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas Estafilocócicas / Vacunas / Staphylococcus aureus Resistente a Meticilina Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas Estafilocócicas / Vacunas / Staphylococcus aureus Resistente a Meticilina Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2024 Tipo del documento: Article